Azilsartan medoxomil

Drug Profile

Azilsartan medoxomil

Alternative Names: Azilsartan kamedoxomil; Azilsartan medoxomil potassium; Edarbi; Ipreziv; TAK-491

Latest Information Update: 19 Feb 2016

Price : $50

At a glance

  • Originator Takeda
  • Class Antihypertensives; Benzimidazoles; Small molecules
  • Mechanism of Action Angiotensin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 01 Feb 2016 Takeda completes a phase III trial in Hypertension in South Korea (NCT02203916)
  • 02 Sep 2015 Takeda plans a phase I pharmacokinetics trial in Healthy volunteers in China (NCT02541669)
  • 01 Sep 2015 Phase-III clinical trials in Hypertension in China (PO) (NCT02480764)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top